Assembly Biosciences, Inc. Adjustments to Additional Paid in Capital, Fair Value
Assembly Biosciences, Inc. (ASMB) reported Adjustments to Additional Paid in Capital, Fair Value of $758.95 thousand for the 12-month period ending 2014-12-31, per its 10-K filed 2017-03-02.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket · last filed 2017-03-02
- Assembly Biosciences, Inc. adjustments to additional paid in capital, fair value for the quarter ending 2014-12-31 was $0.00.
- Assembly Biosciences, Inc. adjustments to additional paid in capital, fair value for fiscal 2014 was $758.95K.
| Period end | Adjustments to Additional Paid in Capital, Fair Value 3 month | Adjustments to Additional Paid in Capital, Fair Value 9 month | Adjustments to Additional Paid in Capital, Fair Value 12 month |
|---|---|---|---|
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-02 | $758.95K 10-K · filed 2017-03-02 | |
| 2014-09-30 | $758.95K 10-Q · filed 2014-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |